Out of 7 analysts covering Epizyme (NASDAQ:EPZM), 8 rate it “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Epizyme was the topic in 7 analyst reports since August 6, 2015 according to StockzIntelligence Inc. H.C. Wainwright upgraded the stock on March 14 to “Buy” rating. Below is a list of Epizyme Inc (NASDAQ:EPZM) latest ratings and price target changes.
14/03/2016 Broker: H.C. Wainwright Old Rating: Neutral New Rating: Buy Old Target: $22.00 New Target: $25.00 Upgrade
09/03/2016 Broker: JMP Securities Rating: Market Outperform Old Target: $42.00 New Target: $28.00 Maintain
10/11/2015 Broker: Wedbush Rating: Outperform Old Target: $42.00 New Target: $33.00 Target Down
The stock increased 5.30% or $0.61 during the last trading session, hitting $12.12. About 596,512 shares traded hands or 63.31% up from the average. Epizyme Inc (NASDAQ:EPZM) has declined 34.08% since August 24, 2015 and is downtrending. It has underperformed by 43.10% the S&P500.
Epizyme, Inc. is a clinical-stage biopharmaceutical firm that discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The company has a market cap of $705.01 million. The Company’s product platform creates small molecule inhibitors of a 96-member class of enzymes known as histone methyltransferases, or HMTs. It currently has negative earnings. The Company’s lead product candidate, EPZ-6438 is an inhibitor that targets the EZH2 HMT.
The institutional sentiment decreased to 1.47 in 2015 Q3. Its down 0.03, from 1.5 in 2015Q2. The ratio is negative, as 14 funds sold all Epizyme Inc shares owned while 24 reduced positions. 17 funds bought stakes while 39 increased positions. They now own 42.10 million shares or 24.69% more from 33.76 million shares in 2015Q2.
Ecor1 Capital Llc holds 8.74% of its portfolio in Epizyme Inc for 1.49 million shares. Nea Management Company Llc owns 5.15 million shares or 4.36% of their US portfolio. Moreover, Foresite Capital Management Ii Llc has 3.94% invested in the company for 1.01 million shares. The Massachusetts-based Mpm Asset Management Llc has invested 3.42% in the stock. Palo Alto Investors Llc, a California-based fund reported 2.12 million shares.
Since May 6, 2015, the stock had 0 insider buys, and 1 sale for $60,380 net activity. Copeland Robert A sold 4,185 shares worth $60,380. Gould Robert J sold 60,000 shares worth $1.19M. Ho Peter Tai-Ching bought 800 shares worth $13,084.
Epizyme Inc - Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with MarketBeat.com’s FREE daily email newsletter.
